WHO warns World Cup travel could unleash deadly hemorrhagic virus in US.

Experts are sounding an alarm regarding a deadly virus capable of causing eye bleeding, warning that the upcoming influx of millions for the World Cup could trigger a disaster America is unprepared to handle. This highly contagious disease carries a fatality rate as high as ninety percent for its most lethal strains, often leaving patients suffering from severe diarrhea, vomiting, and hemorrhaging from the eyes.

On Tuesday, Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, expressed deep concern over the epidemic's rapid expansion. He noted that increased testing and tracing efforts would likely cause the number of reported cases to climb significantly in the coming weeks.

David Dodd, the CEO of vaccine developer GeoVax, told the Daily Mail that the outbreak is scaling with alarming speed. He highlighted that within a few weeks, millions of travelers will arrive in the United States from around the globe for the tournament, creating a genuine concern for public health officials. Dodd emphasized that if the virus enters the country, the consequences would be disastrous for the nation.

A major challenge lies in the virus's asymptomatic incubation phase, which can last up to twenty-one days. Dodd explained that this window makes it extremely difficult to track infected individuals from an epidemiological standpoint. Dr. Arthur Reingold, a professor of epidemiology at the University of California, Berkeley, echoed these fears, stating that the outbreak is spreading particularly fast across the region.

Although there have been seventeen Ebola outbreaks in the Democratic Republic of Congo, this specific event marks only the third outbreak of the Bundibugyo strain. Reingold warned that if large numbers of people gather for the World Cup, it is theoretically possible for one or more infected individuals to be present within that group. Even a single confirmed case appearing in the United States would generate a massive response reaction.

Such an event would drive enormous consternation, fear, and anxiety among the population, ultimately forcing authorities to implement aggressive containment measures. Dodd acknowledged that while the immediate risk is currently very limited, the situation can evolve and spread rapidly due to the highly interconnected nature of today's world.

The Centers for Disease Control and Prevention confirmed on Tuesday that it is working closely with FIFA on safety and screening measures ahead of the World Cup, which begins on June 11. A team from the Democratic Republic of Congo is scheduled to play in Houston, Texas, against Portugal on June 17. On Monday, the agency elevated its travel advisory for the Democratic Republic of Congo to level 3, urging Americans to reconsider nonessential travel.

The agency also announced restricted entry for non-US passport holders who have been in Uganda, the Democratic Republic of Congo, or South Sudan within the past twenty-one days. This travel restriction will remain in effect for the next thirty days. International travelers are already wearing protective face masks at airports like Suvarnabhumi in Thailand as health ministries tighten surveillance on arrivals from high-risk areas.

With the World Cup just weeks away and games planned across the United States, the current risk of an outbreak remains low but could change quickly. The situation highlights a troubling reality where privileged access to information often limits public understanding until a crisis unfolds. Communities face potential risks that are difficult to predict, yet the speed of global travel ensures that localized outbreaks can become national emergencies before containment efforts can fully mobilize.

A World Cup soccer ball stands against the New York City skyline, a symbol of global gathering that masks a lurking biological threat.

David Dodd, chief executive of GeoVax, has issued a stark warning. He argues that millions of international travelers arriving in the United States for the tournament significantly heighten the danger of an Ebola outbreak.

According to Dodd, the rapid expansion of the current epidemic stems from its origins in the Democratic Republic of the Congo and Uganda. These regions are known hotspots where specific viruses thrive within the local environment.

Recent data from the Democratic Republic of the Congo paints a grim picture. Deaths surged more than two-fold in merely four days, climbing to 139 fatalities among 600 suspected cases, according to the World Health Organization.

This marks the seventeenth Ebola flare-up in the Democratic Republic of the Congo. However, it is only the third instance involving the Bundibugyo strain, a variant for which no approved vaccine currently exists.

Officials note that detecting this specific outbreak took time. Some diagnostic tests failed to recognize the rare strain, delaying crucial identification efforts.

GeoVax has developed a promising vaccine candidate for the Bundibugyo strain. This candidate demonstrated significant potential during testing on non-human primates. Yet, the company has not yet released any doses to the public market.

Dodd clarified that vaccines for the Zaire strain are already available. That variant carries a fatality rate reaching up to 90 percent. In contrast, the Bundibugyo strain causes 30 to 50 percent mortality, which is less severe but still deeply frightening.

Reingold explained that Ebola typically spreads when patients show symptoms. This means the incubation period poses less immediate risk to the general public. Nevertheless, if cases emerged in the United States, extensive contact tracing would become necessary.

He described the investigative process officials would employ. Questions would arise such as, if a passenger was on a flight, how do we identify other travelers who shared that plane?

The professor expressed deep concern over the fragmented nature of state-level healthcare responsibilities. These departments rely on CDC funding, which has suffered severe cuts under the Trump administration.

A woman weeps as Red Cross workers carry the coffin of a victim from a health center in Rwampara, Democratic Republic of the Congo.

Reingold acknowledged that local communities could handle a crisis if it appeared in their city. However, he warned they would lack the same capacity they possessed a year or two ago.

Dodd suggested isolation protocols would be incredibly strict in the event of a US outbreak. He pointed to the response to COVID-19, noting fatality rates between 1.5 and 2.5 percent. He urged people to imagine facing a disease with a 50 percent fatality rate.

President Donald Trump addressed the African outbreak at a White House event on Monday. When asked about his concern, he stated, I am concerned about everything, but certainly I am.

On Tuesday, former CDC director Tom Frieden told Reuters he was very worried. He highlighted the diminished ability of the US government and the CDC to respond to such emergencies.

Frieden described the CDC as hollowed out. Thousands of staff members, many specializing in such threats, have been lost.

An analysis by KFF Health News revealed the Trump administration laid off more than 3,000 CDC employees last year. This represents about a quarter of the agency's total staff.

The administration also severely reduced USAID. This agency handles international humanitarian relief and promotes global health. Former CDC and USAID officials noted that the latter could have helped contain the current outbreak in Africa.

When asked if he believed the CDC and federal government were underprepared, Reingold gave a sharp and simple answer. Yes.

Soldiers from a rebel faction stand guard outside a laboratory in the Democratic Republic of Congo where suspected Ebola patients are being tested. The situation remains tense as the virus continues to spread through the region.

As of Wednesday, the outbreak has claimed 139 lives out of 600 suspected cases. Images show women wearing protective masks waiting at a regional hospital for treatment and testing.

Dr. Dodd echoed Dr. Frieden's concerns about the need for multiple vaccine supply sources. He stressed that efficient distribution is just as critical as having the vaccine itself.

"What he's saying is just what all of us have been saying and continue to say in the industry when we're talking about these types of situations," the CEO added.

Dodd explained that true preparedness involves the entire supply chain, not just the final product. "The ability to manufacture what you need" is essential for any effective response.

He also referenced the hantavirus scare that dominated headlines before the current Ebola outbreak. "The concern is not just Ebola," Dodd noted regarding global health threats.

The CDC's press secretary, Emily G Hilliard, told the Daily Mail that the agency maintains extensive expertise in viral hemorrhagic fevers. She stated that CDC experts are fully equipped to protect Americans and mitigate risks.

The agency is working with international partners and Ministries of Health on this evolving situation. Support efforts include technical assistance with disease tracking, contact tracing, and laboratory sample collection in the DRC and Uganda.

CDC resources also cover virus sequencing, infection prevention, local border screening, and coordination with affected countries. Distribution of personal protective equipment and risk communication remain key priorities.

The number of Ebola cases in Central Africa has more than doubled since last week. WHO Director Tedros Adhanom Ghebreyesus expressed that he is "deeply concerned" by this rapid increase.

Approved vaccines exist for the Zaire Ebola strain, but it remains unclear how much protection they offer against the Bundibugyo strain. Images of Ebola virus particles illustrate the microscopic threat facing communities.

Dodd lamented that pharmaceutical companies typically take a reactionary approach to vaccine development. If historical outbreaks are rare, as with the Bundibugyo strain, large companies may ask if there is a market need.

"If we develop that one, will we ever make money off of it?" Dodd asked, highlighting the financial reality driving private sector decisions.

Reingold agreed that developing drugs or vaccines for Ebola is probably not profitable for the average for-profit company. Consequently, the private sector is unlikely to invest heavily in these treatments without government support.

Dodd noted that existing Zaire vaccines might offer some protection against the Bundibugyo strain, but full immunity could take months to over a year to develop.

An mRNA vaccine, the same platform used for rapid COVID vaccine development, would take three to six months. Dodd called this "awfully fast," but warned that such vaccines struggle against virus mutations.

Other platforms based on proteins could provide more flexible protection against mutations, but they might take up to 18 months to develop.

Dodd also criticized governments for reacting only during a crisis. "In general, policymakers, politicians, all tend to respond well in the eye of the storm or that crisis time period," he said.

He concluded that both pharmaceutical companies and governments must adopt proactive approaches to vaccine development before outbreaks occur.

Tom Frieden, the former director of the US Centers for Disease Control, has issued a stark warning that the nation remains critically unprepared for a potential Ebola outbreak. Drawing on decades of experience within the public health sector, Frieden and his colleagues argue that sustained vigilance and rigorous preparation are essential, yet current readiness levels fall far short of what is required.

Amidst these concerns, GeoVax, a small pre-revenue enterprise consisting of just 25 employees, has achieved a significant milestone with its Ebola Zaire vaccine. According to Dodd, the company's formulation demonstrated 100 percent protection during testing on non-human primates. However, the organization's primary strategic objective is to develop and deploy a monkeypox vaccine by early 2028. This initiative targets a specific vulnerability in the global market: the current reliance on a single supplier, Bavarian Nordic, for vaccines against the disease. Dodd aims to dismantle this monopoly, fostering a more resilient supply chain that aligns with his philosophy that vaccine manufacturers must proactively anticipate diverse outbreak scenarios.

In response to the escalating threat, the World Health Organization has gathered a panel of experts to evaluate which existing immunizations can be repurposed or rapidly adapted for emergency deployment. Several candidates have emerged as particularly promising, including products from Merck & Co, Auro Vaccines LLC, and a Chinese-developed mRNA vaccine. Despite their potential, significant limitations persist. Merck & Co's vaccine is currently authorized solely for the Zaire strain and lacks specific approval for the Bundibugyo variant. Meanwhile, while Auro Vaccines LLC and the Chinese-developed option show efficacy against the strain circulating in the current outbreak, both remain in the early stages of development and research, highlighting the precarious gap between scientific promise and immediate availability.